C1259051||TRIB3
C0013081||downregulation
C0013089||doxorubicin
C0596402||cytotoxicity
C0024623||gastric cancer
C0334227||cells
C1259051||TRIB3
C0033684||pseudokinase
C1327622||regulate multiple pro-survival pathways
C0087111||therapeutic
C0920425||treatment
C0086418||human
C0027651||tumors
C0006826||cancer
C1259051||TRIB3
C0428479||protein levels
C0278250||good
C0278252||poor prognosis
C1259051||TRIB3
C1171362||expression
C0007620||survival
C0024623||gastric cancer
C0334227||cells
C0003392||anticancer drugs
C0003392||anticancer drug
C0013089||doxorubicin
C0596402||cytotoxicity
C1540055||TRIB3
C0040649||transcription
C0162638||apoptotic cell death
C1099354||TRIB3 siRNA
C2350567||knockdown
C0013089||doxorubicin
C0162638||apoptosis
C0024623||gastric cancer
C0334227||cells
C1171362||expression
C0522506||downstream
C0763396||apoptotic factors
C1514559||overexpression
C1259051||TRIB3
C0007634||protected cells
C0013089||doxorubicin
C0162638||apoptosis
C0013081||downregulation
C1259051||TRIB3
C0007587||cell death
C0013089||doxorubicin
C0162638||apoptosis
C2986514||anti-apoptotic
C1259051||TRIB3
C0017391||inductions
C0752312||MAPKs
C0013089||doxorubicin
C1259051||TRIB3
C0013081||downregulation
C1259051||TRIB3
C1514559||overexpression
C0013089||doxorubicin
C1155551||MAPK activation
C2825141||findings
C1259051||TRIB3
C2986514||anti-apoptotic
C0013089||doxorubicin
C0024623||gastric cancer
C0334227||cell lines
C1259051||TRIB3
C1171362||expression
C0003392||anticancer drugs
C0013089||doxorubicin
C0123931||irinotecan
C0069717||oxaliplatin
C0920425||cancer therapy